Head to Head Contrast: Lisata Therapeutics (LSTA) versus The Competition

Lisata Therapeutics (NASDAQ:LSTA) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Lisata Therapeutics to similar companies based on the strength of its analyst recommendations, valuation, dividends, risk, institutional ownership, profitability and earnings.

Institutional and Insider Ownership

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 8.4% of Lisata Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Lisata Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Lisata Therapeutics’ competitors have a beta of 1.14, suggesting that their average share price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Lisata Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1	2	0	0	1.67
Lisata Therapeutics Competitors	9789	15054	45300	1571	2.54

As a group, “Biotechnology” companies have a potential upside of 97.60%. Given Lisata Therapeutics’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Lisata Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Lisata Therapeutics Competitors	-9,046.59%	-199.78%	-30.61%

Valuation and Earnings

This table compares Lisata Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lisata Therapeutics	$170,000.00	-$16.59 million	-0.66
Lisata Therapeutics Competitors	$691.13 million	$10.43 million	-10.02

Lisata Therapeutics’ competitors have higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Lisata Therapeutics competitors beat Lisata Therapeutics on 10 of the 12 factors compared.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.